Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases

Background: Vedolizumab (vedo) is effective for induction and maintenance of remission in adults with inflammatory bowel disease (IBD). Pediatric data are still limited, especially for the youngest children with very early onset disease (VEO-IBD). The aim of this study was to assess the safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabiszewska, Sylwia, Derda, Edyta, Szymanska, Edyta, Osiecki, Marcin, Kierkus, Jaroslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268556/
https://www.ncbi.nlm.nih.gov/pubmed/34279480
http://dx.doi.org/10.3390/jcm10132997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268556/
https://www.ncbi.nlm.nih.gov/pubmed/34279480
http://dx.doi.org/10.3390/jcm10132997

Ejemplares similares